Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Chemicals & Petrochemicals | Small Cap
Health Score : 7.47Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.
Health Score : 7.47Saroja Pharma Industries India Ltd demonstrates a mixed financial performance. The company shows strong solvency and profitability, indicating a solid foundation. Efficiency ratios are also notable, driven by high turnover in fixed assets and inventory. However, liquidity is a concern, with low cash and operating cash flow ratios. Growth metrics present a varied picture, with strong revenue and asset growth offset by a decline in earnings per share. The company's coverage ratios are also weak, reflecting limited ability to cover interest and dividends. These factors suggest that while the company is profitable and growing, it needs to strengthen its short-term financial health and improve earnings efficiency. Future success depends on balancing growth initiatives with sustainable financial practices.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
11.08
Industry Median
22.59
Small Cap Median
21.70
P/E RATIO
13.67
P/B RATIO
0.87
Industry Median
1.76
Small Cap Median
1.77
P/S RATIO
0.26
Industry Median
0.89
Small Cap Median
0.88
Others
PEG RATIO
0.00
EV/EBITDA RATIO
4.71
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹35 as on Jun 15, 2026.
Growth Score : 8.00The company demonstrates strong growth in revenue and assets, but earnings per share growth is a concern. High growth rates in revenue and assets indicate successful expansion, while negative EPS growth suggests challenges in translating revenue into profits. This mixed performance requires attention to improve profitability alongside growth.
Revenue Growth RateExcellentOperating Profit Growth RateExcellent
Earnings Per Share (EPS) GrowthPoorAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 51.75 | -9.78 | -18.97 | 32.11 | 30.73 |
| Operating Profit Growth Rate | 61.54 | 29.52 | -5.88 | 8.59 | 37.05 |
| Earnings Per Share (EPS) Growth | -93.08 | -92.85 | -39.34 | 16.89 | 57.42 |
| Asset Growth Rate | 88.69 | 37.59 | 24.51 | 48.85 | 5.56 |
| Net Income Growth Rate | 56.16 | -7.02 | -16.98 | 17.05 | 57.28 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Saroja Pharma Industries India Ltd | 7.47 | 13.67 | Neutral | 3.81 | 4.02 | 1.62 |
| 2 | Sanginita Chemicals Ltd | 7.17 | 62.58 | Undervalued | -6.00 | -3.74 | -10.00 |
| 3 | Yasons Chemex Care Ltd | 5.91 | 19.08 | Neutral | -0.59 | 0.49 | 0.94 |
| 4 | Vadivarhe Speciality Chemicals Ltd | 4.07 | -3.15 | Highly Undervalued | -6.42 | -7.25 | -9.27 |
| 5 | Omkar Speciality Chemicals Ltd | N/A | N/A | N/A | N/A | N/A | N/A |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Strong Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Saroja Pharma Industries India Ltd is engaged in the manufacturing, trading, and supply of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Chemicals, and Solvents. The company also offers contract manufacturing services for its product range, catering primarily to the pharmaceutical, dyes, and paints industries in India.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Saroja Pharma Industries India Ltd's P/E ratio (TTM) is 11.08, compared to the industry median of 22.59 and large cap median of 21.70.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Saroja Pharma Industries India Ltd's P/B ratio is 0.87, compared to the industry median of 1.76 and large cap median of 1.77.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Saroja Pharma Industries India Ltd's P/S ratio is 0.26, compared to the industry median of 0.89 and large cap median of 0.88.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Saroja Pharma Industries India Ltd's PEG ratio is N/A.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Saroja Pharma Industries India Ltd's EV/EBITDA ratio is 4.71.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Saroja Pharma Industries India Ltd's ROE is 9.37%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Saroja Pharma Industries India Ltd's ROA is 9.13%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Saroja Pharma Industries India Ltd's ROCE is 13.02%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Saroja Pharma Industries India Ltd's operating margin is 5.42%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Saroja Pharma Industries India Ltd's net margin is 2.31%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Saroja Pharma Industries India Ltd's current ratio is 1.09.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Saroja Pharma Industries India Ltd's debt-to-equity ratio is 0.43.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Saroja Pharma Industries India Ltd's interest coverage ratio is 2.53.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Saroja Pharma Industries India Ltd's DPS is ₹0.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Saroja Pharma Industries India Ltd's EPS is 57.42.
(Source line: "Ratios as of 15 Jun 2026, based on last traded price of ₹35. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Saroja Pharma Industries India Ltd was incorporated in 2003 as Saroja Pharma Industries Private Limited. Over the years, the company expanded its operations in the manufacturing and trading of a diverse range of chemical products, including APIs and pharma intermediates. In 2023, it successfully completed its IPO and listed on the NSE SME Emerge platform, marking a significant milestone in its corporate journey and allowing it to raise capital for further expansion.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Trading (APIs, Pharma Intermediates, Solvents, Bulk Chemicals) | N/A | Operating Profit |
| Manufacturing (APIs & Pharma Intermediates) | N/A | Operating Profit |
| Custom Synthesis / Contract Manufacturing | N/A | Operating Profit |
Mr. Santhosh Kumar Saroja (Chairman & Managing Director): Holds a Bachelor of Technology degree and possesses over two decades of experience in the pharmaceutical and chemical industries, guiding the company's strategic direction and growth initiatives. Mr. Anil Kumar Saroja (Whole-time Director & CFO): Holds a Bachelor of Commerce degree and is instrumental in overseeing the company's financial management, operational efficiency, and administrative functions.
No major subsidiaries reported.
No major recent corporate actions on record.
References
The Saroja Pharma Industries India Ltd share price today is ₹35 on NSE (SAROJA), as of 12 Aug 2026.
As of 15 Jun 2026, Saroja Pharma Industries India Ltd share price is ₹35, with previous close ₹N/A. Today's range is ₹N/A to ₹N/A. The 52-week range is ₹N/A to ₹N/A.
As of today, Saroja Pharma Industries India Ltd's market cap is ₹14 crore (Small Cap).
Saroja Pharma Industries India Ltd's current P/E ratio is 11.08, compared to the CHEMICALS & PETROCHEMICALS sector average of 32.50.
Saroja Pharma Industries India Ltd's current P/B ratio is 0.87.
Saroja Pharma Industries India Ltd's current dividend yield is N/A. Last dividend of ₹0.00 per share was declared on N/A.
Saroja Pharma Industries India Ltd's EPS (TTM) is ₹57.42.
Saroja Pharma Industries India Ltd is engaged in the manufacturing, trading, and supply of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Chemicals, and Solvents. The company also offers contract manufacturing services for its product range, catering primarily to the pharmaceutical, dyes, and paints industries in India.
Saroja Pharma Industries India Ltd is promoted by Santhosh Kumar Saroja and Anil Kumar Saroja, holding 73.02% as of 15 Jun 2026.
Saroja Pharma Industries India Ltd is listed on NSE (SAROJA) and BSE ({bse}). Its next quarterly results are expected on August 2024 (Q1 FY25).
Adjusted Earnings Per Share (Adjusted EPS)